selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients ...

si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44% achieved clear or

Related Keywords

Germany ,Martinsried ,Bayern ,Munich ,San Diego ,California ,United States ,Ludger Wess Ines Regina Buth ,Andreas Klostermann ,Steve Zaniboni ,Lion Inc ,Chief Scientific Officer ,Antonius Schuh ,Global Source ,Ludger Wess ,Business ,